103 related articles for article (PubMed ID: 7586409)
1. Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma.
DiMaio JM; Van Trigt P; Gaynor JW; Davis RD; Coveney E; Clary BM; Lyerly HK
Circulation; 1995 Nov; 92(9 Suppl):II202-5. PubMed ID: 7586409
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
[TBL] [Abstract][Full Text] [Related]
3. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
5. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
[TBL] [Abstract][Full Text] [Related]
6. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
[TBL] [Abstract][Full Text] [Related]
7. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic effect of agonistic CD40 monoclonal antibody combined with CTL on hu-SCID mouse B lymphoma model].
Zhou H; Xi H; Ma QR; Chen C; Zhang F; Zhang XG; Gu ZJ
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):181-5. PubMed ID: 17649632
[TBL] [Abstract][Full Text] [Related]
9. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
10. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
[TBL] [Abstract][Full Text] [Related]
12. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.
Haque T; Taylor C; Wilkie GM; Murad P; Amlot PL; Beath S; McKiernan PJ; Crawford DH
Transplantation; 2001 Oct; 72(8):1399-402. PubMed ID: 11685111
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas.
Cho HI; Hong YS; Lee MA; Kim EK; Yoon SH; Kim CC; Kim TG
Int J Hematol; 2006 Jan; 83(1):66-73. PubMed ID: 16443556
[TBL] [Abstract][Full Text] [Related]
14. CD8high (CD57+) T cells in normal, healthy individuals specifically suppress the generation of cytotoxic T lymphocytes to Epstein-Barr virus-transformed B cell lines.
Wang EC; Lehner PJ; Graham S; Borysiewicz LK
Eur J Immunol; 1994 Nov; 24(11):2903-9. PubMed ID: 7525311
[TBL] [Abstract][Full Text] [Related]
15. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
[TBL] [Abstract][Full Text] [Related]
16. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
[TBL] [Abstract][Full Text] [Related]
17. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
18. [Ex vivo inducing cultured Epstein-Barr virus specific cytotoxic T lymphocytes and evaluation of their killing effect].
Chen GH; Gu B; Chen F; Wang Y; Qiao M; Liu HW; Feng YF; Dai LJ; Zhu ZL; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1597-601. PubMed ID: 24370055
[TBL] [Abstract][Full Text] [Related]
19. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice.
Buchsbaum RJ; Fabry JA; Lieberman J
Immunol Lett; 1996 Sep; 52(2-3):145-52. PubMed ID: 8905410
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of human EBV-specific cytotoxic T lymphocytes utilized for adoptive immunotherapy of EBV-induced lymphoproliferations in xenografted SCID mice.
Lacerda JF; O'Reilly RJ
Ann Oncol; 1997; 8 Suppl 2():137-40. PubMed ID: 9209657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]